Jaguar Health, Inc. has made a significant move by declaring a special dividend that involves the conversion of its Series R Convertible Preferred Stock into common stock. This decision, announced in a recent SEC filing, underscores the company's commitment to enhancing shareholder value and reflects its ongoing financial strategy.

The special dividend was paid on October 15, 2026, granting one share of Series R Convertible Preferred Stock for each share of voting common stock outstanding as of October 13, 2026. Following this, the Series R Preferred Stock automatically converted into common stock on November 2, 2026, resulting in a total of 13,345,986 shares of common stock issued and outstanding.

Background

Jaguar Health, Inc. operates in the pharmaceutical preparations industry, specifically focusing on developing and commercializing novel gastrointestinal products. The company trades under the ticker symbol JAGX on the Nasdaq exchange. Its recent filings indicate a proactive approach to enhancing its market position and shareholder engagement.

What the Filing Says

The SEC filing states, "As previously disclosed, on October 15, 2026, Jaguar Health, Inc. paid a special one-time dividend of one share of Series R Convertible Preferred Stock for each share of voting common stock outstanding." It further details that on November 2, 2026, these shares automatically converted into five shares of common stock.

Impact

This development could have a ripple effect across the pharmaceutical preparations sector, prompting competitors to evaluate their own dividend policies and shareholder engagement strategies. The conversion of preferred stock into common stock may also attract more investors looking for equity in a growing company.

What's Next

The filing does not specify what happens next, leaving stakeholders to anticipate further announcements from the company regarding its future plans and strategies.